2025 ALS Guidelines: Core Recommendations
Multidisciplinary care is the standard of care for ALS and should be delivered through an integrated hub-and-spoke system with expedited access to respiratory support, equipment, and Medicare coverage regardless of age or employment status 1.
Multidisciplinary Care Model (Standard of Care)
Multidisciplinary clinics are associated with:
- Prolonged survival
- Decreased healthcare utilization
- Higher quality of life
The 2024 NASEM guidelines recommend a reimagined three-tiered hub-and-spoke system 1:
- Comprehensive ALS centers (NINDS-designated, analogous to NCI cancer centers)
- Regional centers
- Community-based multidisciplinary centers (expanding access to underserved areas)
All centers should provide coordinated care involving neurologists, physiatrists, pulmonologists, physical/occupational therapists, speech-language pathologists, respiratory therapists, nutritionists, and social workers 2.
Respiratory Management (Critical for Mortality)
Respiratory assist devices (RAD) should be provided earlier than current Medicare criteria allow, without waiting for FVC to drop below 50% 1. The current Medicare threshold is outdated and misaligned with best practices—respiratory failure is the primary cause of death in ALS, and RAD improves both quantity and quality of life 1.
Key recommendations:
- Align coverage with current American College of Chest Physicians guidelines (not the arbitrary 50% FVC cutoff)
- Provide in-home respiratory care and services
- Include respiratory therapy as part of routine home health services 2
Equipment and Services Access
All requests for equipment and services should be considered urgent and handled expeditiously 1. This includes:
- Mobility aids (wheelchairs, walkers, lifts)
- Communication devices
- Home modifications
- Home health services—even when disease progression results in "failure to improve" (a common insurance denial trigger) 1
The guidelines explicitly state that home health authorization should not be denied based on disease progression 1.
Disease-Modifying Therapies
Current evidence-based pharmacological options include 3, 4:
Standard therapies:
- Riluzole (modest benefit on survival)
- Edaravone (IV or oral formulation—oral has comparable pharmacokinetics with easier administration) 4
Newer therapies:
- High-dose intramuscular mecobalamin (reduces functional decline when started early) 4
- Tofersen (antisense oligonucleotide for SOD1-related ALS—first gene-targeted therapy, requires genetic testing) 3, 4
Critical caveat: Genetic testing and counseling should be performed in all ALS cases to identify candidates for targeted therapies like tofersen 4. Up to 3-4 anti-ALS agents can now be combined, though long-term safety and synergistic effects require further study 4.
Home Health Services (Stage-Responsive)
The 2026 AANEM guidelines emphasize proactive, anticipatory care rather than reactive responses to functional decline 2:
- Nursing care for medication management, symptom monitoring
- Home health aides for activities of daily living
- Physical/occupational therapy for mobility, adaptive equipment training
- Speech-language pathology for dysphagia and communication
- Respiratory therapy for airway clearance, ventilation management
- Nutritional support (early gastrostomy consideration before respiratory compromise)
- Social work for care coordination and caregiver support
Insurance and Access Priorities
Near-term policy recommendations (Recommendations 3-1 through 3-5) 1:
- Expand Medicare eligibility to all persons with ALS regardless of age, employment history, or other factors 1
- Require adequate reimbursement for multidisciplinary ALS care (currently insurance covers less than half of costs) 1
- Provide caregiver support including tax relief and financial assistance 1
- Improve racial and ethnic equity—Black Americans face significantly worse outcomes and need targeted interventions 1
Palliative Care Integration
Palliative care should be integrated from diagnosis, not reserved for end-of-life 5, 2. This includes:
- Pain management
- Spasticity control
- Psychological support for patients and caregivers
- Advanced care planning discussions
- End-of-life decision support
Asia-Pacific Specific Considerations
The 2025 PACTALS guidelines address resource-limited settings 6, emphasizing:
- Diagnostic pathways appropriate for low- and middle-income countries
- Adapted multidisciplinary models
- Management of cognitive/behavioral symptoms
- Culturally appropriate palliative care
Common Pitfalls to Avoid
- Waiting for FVC <50% to initiate respiratory support—this delays life-prolonging intervention 1
- Denying home health services due to "failure to improve"—ALS is progressive by definition; this criterion is inappropriate 1
- Delaying genetic testing—this prevents access to targeted therapies like tofersen 4
- Reactive rather than anticipatory equipment provision—leads to preventable complications and hospitalizations 2
- Inadequate caregiver support—caregiver burnout directly impacts patient outcomes 1